BPC-157 and TB-500 as a pair, read against the literature
The BPC-157 and TB-500 combination, often marketed as a recovery stack, on the evidence: what each compound does in animal models, why no human trial has tested the pair, and what the enthusiasm rests on.
By The PepVise Editorial Team · Reviewed August 6, 2026 · 9 min read
Side-by-side comparisons on PepVise rank by weight of evidence, not by bodybuilding forum consensus. Tier badges on every entry.
How we read the literature
- Evidence tier
- We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
- Trial stage
- Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
- Regulatory status
- We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
- Where we're uncertain
- Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.
What readers ask us next.
- Is stacking BPC-157 and TB-500 proven to work?
- No. There is no controlled human trial of the two compounds taken together, and no published preclinical study of the specific combination. Each has separate animal data, mostly in rats, but combining two individually unapproved compounds does not create evidence for the pair. The stack is a hypothesis, not a demonstrated therapy.
- Are BPC-157 and TB-500 approved by the FDA?
- Neither is an approved drug for human use in the United States, and both are typically sold labeled for research use only. In 2023 the FDA placed BPC-157 in a category that effectively bars it from compounding under the relevant provisions. That regulatory status is separate from any efficacy claim.
- What is the difference between TB-500 and thymosin beta-4?
- Most of the regenerative research describes full-length thymosin beta-4, the natural 43-amino-acid peptide. TB-500 is marketed as a related fragment, and the two are frequently treated as interchangeable in sales copy, but the published wound-healing and cardiac-repair data largely used the full molecule, so extrapolating it to the fragment is an assumption.
- Is the combination safe?
- Its safety in humans is not established. Long-term human safety data does not exist for either compound individually, let alone together, and research-grade material carries purity and contamination risks. Absence of reported harm on forums is not the same as demonstrated safety.
A new Phase 2 trial for any of the ranked compounds. A regulatory action changing FDA status. A published replication failure in an independent lab. Any of those would move entries on this list within a week, with a dated note on what changed.
References cited on this page.
PubMed, ClinicalTrials.gov, and FDA documents only. Secondary sources appear when needed to characterize public discourse, never as a source for a clinical claim.
- [01]Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res 2003;21:976-983
- [02]Krivic A et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing. J Orthop Res 2006;24:982-989
- [03]Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999
- [04]Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012
- [05]Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des 2011
About The Pepvise Editorial Team
The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.
Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →
Adjacent in the literature.
GHK-Cu Topical vs Injection: Where the Evidence Sits
GHK-Cu topical versus injection on the evidence: why nearly all the human-relevant data is topical, why injectable use has no trial and raises copper-safety questions, and how to read the two routes honestly.
8 min readEvidence · ExplainerGHK-Cu Before and After: What to Expect From the Evidence
GHK-Cu before-and-after on the evidence: what the skin and hair studies actually measured, why online transformation photos are not trial data, and a realistic view of the timeframes and magnitudes involved.
7 min readEvidence · ExplainerPeptides for Healing: What the Evidence Actually Supports
Peptides for healing on the evidence: which repair-associated peptides have human data, which rest on animal wound-healing models, and why the strongest healing peptide is one most people already know.
9 min readGet the 2026 Peptide Evidence Ledger.
A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.
By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.